Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis

British Journal of Clinical Pharmacology

Volumn 74, Issue 6, 2012, Pages 971-977

  Bouazza, Naïm ^a,b   Pestre, Vincent ^c   Jullien, Vincent ^c   Curis, Emmanuel ^a   Urien, Saïk ^a,b,d   Salmon, Dominique ^c   Tréluyer, Jean Marc ^a,b,c,d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Paris Descartes University   (France)

^c université Paris Cité   (France)

^d INSERM   (France)

Author keywords

Clindamycin; Osteomyelitis; Population pharmacokinetics

Indexed keywords

CLINDAMYCIN; RIFAMPICIN;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; COMPARTMENT MODEL; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HUMAN; MALE; OSTEOMYELITIS; PRIORITY JOURNAL;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; BODY WEIGHT; CLINDAMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; OSTEOMYELITIS; RETROSPECTIVE STUDIES; RIFAMPIN; YOUNG ADULT;

EID: 84869004679     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04292.x     Document Type: Article

References (22)

1. Lazzarini L, Lalla F, de, Mader JT. Long bone osteomyelitis. Curr Infect Dis Rep 2002; 4: 439-45.
2. Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? Int J Infect Dis 2005; 9: 127-38.
3. Mandell GL, Bennett JE, Dolin R. Principles and Practice of Infectious Diseases, 5th edn. on CD-ROM. 5th éd. Philadelphia, PA: Churchill Livingstone, 2000.
4. Dornbusch K, Carlström A, Hugo H, Lidströlm A. Antibacterial activity of clindamycin and lincomycin in human bone. J Antimicrob Chemother 1977; 3: 153-60.
5. Panzer JD, Brown DC, Epstein WL, Lipson RL, Mahaffey HW, Atkinson WH. Clindamycin levels in various body tissues and fluids. J Clin Pharmacol 1972; 12: 259-62.
6. Plott MA, Roth H. Penetration of clindamycin into synovial fluid. Clin Pharmacol Ther 1970; 11: 577-80.
7. Mayberry-Carson KJ, Mayberry WR, Tober-Meyer BK, Costerton JW, Lambe DW Jr. An electron microscopic study of the effect of clindamycin on adherence of Staphylococcus aureus to bone surfaces. Microbios 1986; 45: 21-32.
8. Mayberry-Carson KJ, Tober-Meyer B, Lambe DW Jr, Costerton JW. An electron microscopic study of the effect of clindamycin therapy on bacterial adherence and glycocalyx formation in experimental Staphylococcus aureus osteomyelitis. Microbios 1986; 48: 189-206.
9. Gisby J, Beale AS, Bryant JE, Toseland CDN. Staphylococcal osteomyelitis - a comparison of co-amoxiclav with clindamycin and flucloxacillin in an experimental rat model. J Antimicrob Chemother 1994; 34: 755-64.
10. Mader JT, Adams K, Morrison L. Comparative evaluation of cefazolin and clindamycin in the treatment of experimental Staphylococcus aureus osteomyelitis in rabbits. Antimicrob Agents Chemother 1989; 33: 1760-4.
11. El Samad Y, Havet E, Bentayeb H, Olory B, Canarelli B, Lardanchet J-F, Douadi Y, Rousseau F, Lescure FX, Mertl P, Eb F, Schmit JL. Treatment of osteoarticular infections with clindamycin in adults. Med Mal Infect 2008; 38: 465-70.
12. Geddes AM, Dwyer NSJ, Ball AP, Amos RS. Clindamycin in bone and joint infections. J Antimicrob Chemother 1977; 3: 501-7.
13. Zeller V, Dzeing-Ella A, Kitzis M-D, Ziza J-M, Mamoudy P, Desplaces N. Continuous clindamycin infusion, an innovative approach to treating bone and joint infections. Antimicrob Agents Chemother 2010; 54: 88-92.
14. Pharmacia Limited. Dalacin, Summary of Product Characteristics. Sandwich: Pharmacia Limited, 2010 25 May Posting Date.
15. Lavielle M, Mentré F. Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software. J Pharmacokinet Pharmacodyn 2007; 34: 229-49.
16. Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J 2009; 11: 558-69.
17. Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comput Graph Stat 1996; 5: 299-314.
18. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 2011; 13: 143-51.
19. Comets E, Brendel K, Mentré F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 2008; 90: 154-66.
20. Vidaillac C, Parra-Ruiz J, Winterfield P, Rybak MJ. In vitro pharmacokinetic/pharmacodynamic activity of NXL103 versus clindamycin and linezolid against clinical Staphylococcus aureus and Streptococcus pyogenes isolates. Int J Antimicrob Agents 2011; 38: 301-6.
21. Zeller V, Desplaces N. Antibiothérapie des infections ostéoarticulaires à pyogènes chez l'adulte?: principes et modalités. Rev Rhum 2006; 73: 183-90.
22. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10. quiz 11-12.